Get the Stockscreener App
0.406
4.10%
0.016
After Hours:
.40
-0.006
-1.48%
Jaguar Health Inc stock is traded at $0.406, with a volume of 689.56K.
It is up +4.10% in the last 24 hours and down -19.28% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$0.39
Open:
$0.4
24h Volume:
689.56K
Relative Volume:
0.18
Market Cap:
$5.04M
Revenue:
$11.51M
Net Income/Loss:
$-54.00M
P/E Ratio:
-0.0111
EPS:
-36.5591
Net Cash Flow:
$-23.73M
1W Performance:
-0.85%
1M Performance:
-19.28%
6M Performance:
-79.03%
1Y Performance:
-91.43%
1-Day Range:
$0.3751
$0.4162
1-Week Range:
$0.3401
$0.4498
52-Week Range:
$0.313
$14.07
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.406 | 4.58M | 11.51M | -54.00M | -23.73M | -36.56 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs - Bitget
Jaguar Health plans AI use for rare disease drug development By Investing.com - Investing.com Australia
Jaguar Health (JAGX) Enhances Development with AI Technology - GuruFocus
Macro Review: Is Jaguar Health Inc gaining market share2026 Big Picture & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Jaguar Health plans AI use for rare disease drug development - Investing.com
No-treatment pediatric disorder drives Jaguar's AI push for crofelemer - Stock Titan
Jaguar Health Inc (JAGX) Q4 2025 Earnings Call Highlights: Reven - GuruFocus
Earnings call transcript: Jaguar Health Q4 2025 misses EPS, revenue targets By Investing.com - Investing.com South Africa
Earnings call transcript: Jaguar Health Q4 2025 misses EPS, revenue targets - Investing.com India
JAGX: Q4 2025 revenue up 5% sequentially; major out-license deal secures $16M for rare disease focus - TradingView — Track All Markets
JAGX Stock Chart | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Health to Host Investor Webcast on Q4 2025 Financials - National Today
Jaguar Health, Inc. Files Form 8-K with SEC Detailing Company Information and NASDAQ Listing (April 2026) - Minichart
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates - ACCESS Newswire
Jaguar Health reports improved stockholders’ equity after recent transactions - Investing.com
Jaguar Health reports improved stockholders’ equity after recent transactions By Investing.com - Investing.com South Africa
Jaguar Animal Health Regains Nasdaq Compliance Through Capital Infusions - TipRanks
Jaguar Health says equity rebuilt above Nasdaq minimum after financing, inventory and debt adjustments - TradingView — Track All Markets
Jaguar Health (NASDAQ: JAGX) details equity boost after deficit - Stock Titan
Investment Recap: Is Jaguar Health Inc stock a top performer YTDWeekly Loss Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Jaguar Health completes diarrhea study in dogs on chemo By Investing.com - Investing.com Canada
Jaguar Health (JAGX) Advances Canalevia-CA1 Study for Chemothera - GuruFocus
Jaguar Health completes diarrhea study in dogs on chemo - Investing.com
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Dog cancer-treatment diarrhea drug nears FDA filing after trial - Stock Titan
JAGX Fundamental Analysis & Valuation | Fair Value & Financial Strength | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Health (JAGX.US) will release its earnings report before the market opens on April 10. - 富途牛牛
Jaguar Health, Inc. (JAGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Jaguar Health Reports 2025 Financials - marketscreener.com
JAGX Sees Slight Revenue Decline Amid Decrease in Mytesi Prescri - GuruFocus
Jaguar Health Reports 2025 Financial Results: 5% Q4 Revenue Growth, $16M Up-Front License Deal, and Nasdaq Compliance Appeal 1 - Minichart
Wider 2025 loss, $16M Future Pak deal and Nasdaq risk for Jaguar Health (JAGX) - Stock Titan
Jaguar lands $16M license payment as Nasdaq delisting is stayed - Stock Titan
Jaguar Health, Inc. 2025 Annual Report: Key Financials, Agreements, and Business Segment Highlights - Minichart
Jaguar Health 2025 10-K: $11.51M Revenue, ($22.97) EPS - TradingView — Track All Markets
Jaguar Health (NASDAQ: JAGX) leans into rare GI drugs and $16M Mytesi deal - Stock Titan
Day Trade: Is Jaguar Health Inc stock showing strong momentumRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Rate Cut: Will Jaguar Health Inc benefit from AI trends2026 Trading Volume Trends & Low Risk Entry Point Tips - baoquankhu1.vn
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress - ACCESS Newswire
JAGX Q4'25 Earnings: EPS estimate is (4.26) USD - TradingView — Track All Markets
Children needing IV nutrition cut support 12%-37% in crofelemer study - Stock Titan
Jaguar Health Delays Annual Form 10-K Filing - TipRanks
Jaguar Health (NASDAQ: JAGX) notifies SEC of late 10-K; will file within 15 days - Stock Titan
Jaguar Health Inc. (JAGX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
JAGX Q4'25 Earnings: revenue estimate is 4.21M USD - TradingView
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Central New Jersey News
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication - burlingtonfreepress.com
Published on: 2026-03-29 01:23:24 - baoquankhu1.vn
Jaguar Health Inc Stock: Commercial-Stage Pharma Targeting Gastrointestinal Disorders in Humans and - AD HOC NEWS
Entry Recap: Is Jaguar Health Inc undervalued by DCF analysisAnalyst Upgrade & Low Risk High Reward Ideas - baoquankhu1.vn
Jaguar Health Inc stock faces extreme dilution risk as proxy seeks massive share increase and dual r - AD HOC NEWS
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):